Document center

Study to evaluate the ERA policy framework and ERA monitoring mechanism

Published on | 2 years ago

Programmes Enhancing EU R&I

The European Research Area (ERA) aims to harmonise the framework conditions for R&I in Europe, and builds on both national and EU level measures on a voluntary basis. To achieve these goals, the ERA Roadmap 2015-2020 set out a framework for implementing the ERA in a more structured way that aimed to strengthen the contribution of national measures to ERA implementation (recognising the crucial role already played by EU measures). Within the ERA Roadmap, the National Action Plans (NAPs) played an important role in setting out the contribution of the Member States and other ERA-participant countries to the ERA. Additionally, the European Research Area and Innovation Committee (ERAC) provided technical inputs to facilitate ERA implementation across the 6 thematic ERA priorities defined in 2012 and incorporated into the ERA Roadmap. The study reviewed ERA governance arrangements in 2015-2020 as well as the monitoring and indicator system. In the context of the revitalised ERA Communication of September 2020, and subsequent Council Conclusions to further elaborate the approach to the new ERA, an assessment was carried out of the new proposed approach to governance arrangements and a new proposed monitoring and indicator system in the form of an ERA Scoreboard and broader performance monitoring framework was developed. This aimed to incorporate the lessons learned to date and reflect the additional EU level priorities to ensure a renewed joint undertaking based on a multi-level governance and partnership-based model. The study presents a set of recommendations for the future. (from the executive summary of the study)

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.